Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Cytokinetics, Incorporated operates as a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of novel small molecule therapeutics that modulate muscle function for the treatment of diseases and medical conditions. Cytokinetics serves customers in the State of California.
Website: cytokinetics.com


  • Bad financial results growth rate 0.0% (average between last period year over year growth for revenue and EBITDA), are preserved at an average historical level (0.0%)
  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield -2.1% (LTM)
  • Share price is 201.7% higher than minimum and 24.9% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (500.0x vs 30.0x)
  • For the last 3 months insiders sold company shares on $17.8 mln (-0.256% of cap.)

Key Financials (Download financials)

Ticker: CYTK
Share price, USD:  (+2.5%)81.11
year average price 61.87  


year start price 37.93 2025-07-23

min close price 33.23 2025-08-11

max close price 87.26 2026-06-29

current price 81.11 2026-07-22
Common stocks: 91 298 898

Dividend Yield:  0.0%
EV / Sales: 2 716.1x
Margin (EBITDA LTM / Revenue): -16 666.7%

Target EV / EBITDA (hist percentile): 30.0x
Express share price potential:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 7 405
Net Debt ($m): 743
EV (Enterprise Value): 8 148
EBITDA LTM (млн $): -500
Price to Book: -13.9x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2026-01-22businesswire.com

The Law Offices of Frank R. Cruz Announces Investigation of Cytokinetics, Incorporated (CYTK) on Behalf of Investors

2026-01-12seekingalpha.com

Cytokinetics, Incorporated (CYTK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

2025-12-22seekingalpha.com

Cytokinetics: Small Label Differences With Big Commercial Stakes

2025-12-22zacks.com

Cytokinetics Wins FDA Approval for Cardiovascular Drug, Stock up

2025-12-22seekingalpha.com

Cytokinetics, Incorporated (CYTK) Discusses FDA Approval of MYQORZO for Symptomatic Obstructive Hypertrophic Cardiomyopathy Transcript

2025-12-19reuters.com

US FDA approves Cytokinetics' heart disease drug

2025-11-19seekingalpha.com

Cytokinetics: A Heavily Mispriced Cardiovascular Platform

2025-11-17prnewswire.com

CYTK Deadline: CYTK Investors Have Opportunity to Lead Cytokinetics, Inc. Securities Fraud Lawsuit

2025-11-17globenewswire.com

Investors in Cytokinetics, Incorporated Should Contact Levi & Korsinsky Before November 17, 2025 to Discuss Your Rights – CYTK

2025-11-17newsfilecorp.com

CYTK DEADLINE: ROSEN, GLOBAL INVESTOR RIGHTS COUNSEL, Encourages Cytokinetics, Inc. Investors to Secure Counsel Before Important November 17 Deadline in Securities Class Action - CYTK
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol CYTK CYTK CYTK CYTK CYTK CYTK CYTK CYTK CYTK CYTK CYTK CYTK CYTK CYTK
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-05 2025-08-07 2024-11-07 2024-08-09 2024-05-10 2023-11-03 2023-08-03 2023-05-05 2022-11-04
acceptedDate 2025-11-05 16:31:00 2025-08-07 16:30:30 2025-02-27 17:05:31 2024-11-07 16:05:36 2024-08-09 16:05:31 2024-05-10 16:05:52 2024-02-28 17:12:28 2023-11-03 17:30:58 2023-08-03 16:14:00 2023-05-05 16:05:47 2023-03-01 16:07:15 2022-11-04 16:42:03 2022-02-25 17:01:54 2021-02-26 16:33:57
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 2M 67M 18M 463 000 249 000 835 000 8M 378 000 867 000 5M 95M 3M 70M 56M
costOfRevenue 3M 2M 339M 85M 2M 2M 330M 83M 83M 79M 241M 63M 160M 97M
grossProfit -743 000 64M -321M -84M -2M -1M -323M -82M -82M -75M -146M -60M -90M -41M
grossProfitRatio -0.384 0.966 -181.747 -8.663 -1.792 -217.339 -94.956 -16.217 -23.944
researchAndDevelopmentExpenses 99M 113M 339M 463 000 77M 79M 330M 378 000 867 000 2M 241M 3M 160M 97M
generalAndAdministrativeExpenses 69M 66M 215M 57M 51M 46M 174M 40M 40M 50M 178M 48M 97M 53M
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 69M 66M 215M 57M 51M 46M 174M 40M 40M 50M 178M 48M 97M 53M
otherExpenses -3M -2M -339M 0 200 000 81M -330M 82M 82M -2M -241M -3M -160M -97M
operatingExpenses 166M 176M 215M 141M 128M 125M 174M 40M 40M 50M 178M 48M 97M 53M
costAndExpenses 169M 178M 555M 141M 130M 127M 504M 123M 123M 129M 419M 111M 257M 150M
interestIncome 10M 13M 52M 17M 12M 8M 28M 7M 7M 6M 11M 4M 331 000 5M
interestExpense 26M 24M 87M 22M 24M 17M 58M 14M 13M 13M 51M 16M 29M 39M
depreciationAndAmortization 3M 2M 10M 2M 2M 2M 12M 7M 7M 6M 8M 6M 10M 2M
ebitda -277M -108M -493M -138M -117M -124M -457M -115M -115M -118M -329M -103M -176M -87M
ebitdaratio -143.17 -1.615 -298.59 -513.116 -148.388 -305.36 -132.953 -25.59 -40.91
operatingIncome -167M -112M -536M -141M -130M -126M -496M -122M -122M -124M -324M -108M -186M -94M
operatingIncomeRatio -86.134 -1.67 -304.106 -522.779 -151.18 -323.452 -140.772 -26.983 -43.118
totalOtherIncomeExpensesNet -139M -23M -53M -20M -13M -9M -30M -7M -7M -7M -65M -34M -29M -33M
incomeBeforeTax -306M -134M -590M -161M -143M -136M -526M -129M -129M -131M -389M -142M -215M -127M
incomeBeforeTaxRatio -158.15 -2.012 -346.749 -575.574 -162.447 -342.386 -148.37 -28.461 -56.584
incomeTaxExpense 0 0 0 0 0 2M 0 0 0 -2M 0 34M 0 0
netIncome -306M -134M -590M -161M -143M -136M -526M -129M -129M -129M -389M -176M -215M -127M
netIncomeRatio -158.15 -2.012 -346.749 -575.574 -162.447 -342.386 -148.37 -28.06 -70.051
eps -2.55 -1.12 -5.26 -1.36 -1.31 -1.33 -5.45 -1.35 -1.34 -1.36 -4.33 -1.88 -2.8 -1.97
epsdiluted -2.55 -1.12 -1.36 -1.31 -1.33 -1.35 -1.34 -1.36 -1.88
weightedAverageShsOut 120M 119M 112M 118M 109M 102M 97M 96M 96M 95M 90M 94M 77M 65M
weightedAverageShsOutDil 120M 119M 112M 118M 109M 102M 97M 96M 96M 95M 90M 94M 77M 65M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-27 2024-02-28 2023-03-01 2022-02-25 2021-02-26
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome -35M -30M -40M -29M -33M
ebit -503M -469M -338M -186M -89M
nonOperatingIncomeExcludingInterest -33M -28M 14M -331 000 -5M
netIncomeFromContinuingOperations -590M -526M -389M -215M -127M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -590M -526M -389M -215M -127M
epsDiluted -5.26 -5.45 -4.33 -2.8 -1.97

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol CYTK CYTK CYTK CYTK CYTK CYTK CYTK CYTK CYTK CYTK CYTK CYTK CYTK CYTK
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-05 2025-08-07 2024-11-07 2024-08-09 2024-05-10 2023-11-03 2023-08-03 2023-05-05 2022-11-04
acceptedDate 2025-11-05 16:31:00 2025-08-07 16:30:30 2025-02-27 17:05:31 2024-11-07 16:05:36 2024-08-09 16:05:31 2024-05-10 16:05:52 2024-02-28 17:12:28 2023-11-03 17:30:58 2023-08-03 16:14:00 2023-05-05 16:05:47 2023-03-01 16:07:15 2022-11-04 16:42:03 2022-02-25 17:01:54 2021-02-26 16:33:57
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 225M 75M 95M 47M 191M 120M 113M 100M 69M 102M 66M 106M 113M 83M
shortTermInvestments 737M 783M 981M 965M 867M 499M 502M 440M 497M 562M 717M 761M 359M 381M
cashAndShortTermInvestments 963M 858M 1 076M 1 012M 1 057M 619M 615M 539M 566M 664M 783M 868M 472M 464M
netReceivables 2M 8M 17M 244 000 0 834 000 1M 2M 985 000 1M 147 000 2M 52M 4M
inventory 0 0 0 0 0 -834 000 0 -2M -985 000 -1M 0 0 0 0
otherCurrentAssets 13M 20M 15M 7M 11M 19M 0 22M 21M 17M 12M 14M 0 0
totalCurrentAssets 977M 887M 1 108M 1 019M 1 068M 639M 628M 561M 587M 681M 795M 884M 536M 474M
propertyPlantEquipmentNet 154M 146M 141M 141M 143M 146M 148M 156M 158M 161M 163M 155M 146M 16M
goodwill 0 0 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
longTermInvestments 289M 178M 145M 269M 305M 15M 41M 15M 27M 40M 47M 29M 152M 37M
taxAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 17M 15M 8M 8M 8M 8M 8M 8M 8M 8M 10M 8M 7M 6M
totalNonCurrentAssets 459M 339M 294M 417M 456M 169M 196M 179M 193M 209M 220M 192M 306M 60M
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 1 437M 1 226M 1 402M 1 436M 1 524M 808M 824M 741M 780M 890M 1 015M 1 076M 841M 534M
accountPayables 22M 16M 20M 12M 9M 13M 22M 14M 13M 17M 26M 14M 21M 8M
shortTermDebt 38M 34M 12M 49M 49M 30M 10M 17M 16M 14M 958 000 16M 0 0
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 2M 1M 52M 0 -38M -40M 0 33M 31M 0 0 0 0 0
otherCurrentLiabilities 81M 80M 21M 49M 45M 86M 40M 14M 6M 44M 23M 46M 16M 13M
totalCurrentLiabilities 142M 131M 180M 110M 103M 89M 103M 78M 66M 75M 85M 76M 72M 31M
longTermDebt 1 159M 824M 646M 759M 760M 607M 607M 731M 734M 736M 610M 723M 143M 136M
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 87M 87M
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 657M 639M 599M 581M 552M 509M 380M 370M 314M 308M 302M 985M 184M 166M
totalNonCurrentLiabilities 1 816M 1 463M 1 357M 1 340M 1 312M 1 115M 1 108M 1 102M 1 047M 1 044M 1 038M 1 015M 526M 389M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 111M 131M 132M 134M 135M 119M 138M 139M 140M 140M 140M 130M 127M 3M
totalLiabilities 1 958M 1 594M 1 537M 1 450M 1 415M 1 204M 1 211M 1 179M 1 113M 1 119M 1 123M 1 092M 597M 420M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 122 000 119 000 118 000 118 000 117 000 105 000 102 000 94 000 94 000 94 000 94 000 93 000 84 000 70 000
retainedEarnings -3 304M -2 998M -2 702M -2 552M -2 391M -2 248M -2 112M -1 975M -1 846M -1 717M -1 586M -1 449M -1 208M -992M
accumulatedOtherComprehensiveIncomeLoss 34 000 -158 000 2M 5M -1M -539 000 -10000 -874 000 -1M -2M -4M -6M -869 000 149 000
othertotalStockholdersEquity 2 782M 2 629M 2 532M 2 501M 1 852M 1 537M 1 514M 1 490M 1 438M
totalStockholdersEquity -521M -369M -135M -14M 109M -396M -386M -439M -333M -229M -108M -16M 244M 113M
totalEquity -521M -369M -135M -14M 109M -396M -386M -439M -333M -229M -108M -16M 244M 113M
totalLiabilitiesAndStockholdersEquity 1 437M 1 226M 1 436M 1 524M 808M 741M 780M 890M 1 076M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 1 437M 1 226M 1 402M 1 436M 1 524M 808M 824M 741M 780M 890M 1 015M 1 076M 841M 534M
totalInvestments 1 026M 961M 1 126M 1 234M 1 172M 514M 542M 455M 524M 562M 764M 790M 511M 418M
totalDebt 1 197M 858M 789M 790M 790M 755M 756M 748M 749M 750M 750M 739M 270M 139M
netDebt 968M 783M 694M 743M 600M 635M 643M 649M 681M 649M 685M 633M 157M 56M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-27 2024-02-28 2023-03-01 2022-02-25 2021-02-26
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 17M 1M 147 000 52M 4M
otherReceivables 0 0 0 0 0
prepaids 0 12M 0 12M 6M
totalPayables 20M 22M 26M 21M 8M
otherPayables 0 0 0 0 0
accruedExpenses 55M 13M 22M 19M 8M
capitalLeaseObligationsCurrent 19M 18M 13M 15M 3M
capitalLeaseObligationsNonCurrent 113M 120M 127M 112M 440 000
treasuryStock 0 0 0 0 0
additionalPaidInCapital 2 564M 1 726M 1 482M 1 452M 1 105M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol CYTK CYTK CYTK CYTK CYTK CYTK CYTK CYTK CYTK CYTK CYTK CYTK CYTK CYTK
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-05 2025-08-07 2024-11-07 2024-08-09 2024-05-10 2023-11-03 2023-08-03 2023-05-05 2022-11-04
acceptedDate 2025-11-05 16:31:00 2025-08-07 16:30:30 2025-02-27 17:05:31 2024-11-07 16:05:36 2024-08-09 16:05:31 2024-05-10 16:05:52 2024-02-28 17:12:28 2023-11-03 17:30:58 2023-08-03 16:14:00 2023-05-05 16:05:47 2023-03-01 16:07:15 2022-11-04 16:42:03 2022-02-25 17:01:54 2021-02-26 16:33:57
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome -306M -134M -590M -161M -143M -136M -526M -129M -129M -131M -389M -142M -215M -127M
depreciationAndAmortization 3M 2M 10M 2M 2M 2M 12M 2M 2M 2M 6M 1M 2M 2M
deferredIncomeTax 0 0 0 0 0 0 0 0 1000 0 0 0 3M -573 000
stockBasedCompensation 31M 28M 98M 25M 25M 22M 72M 19M 19M 15M 48M 13M 27M 18M
changeInWorkingCapital 23M -51M 36M 16M 10M -26M 3M 1M -24M -19M -25M 12M 8M 89M
accountsReceivables 7M -6M -15M -244 000 834 000 449 000 -1M -2M 21 000 -859 000 57M -321 000 -47M 743 000
inventory 0 0 0 0 0 0 0 0 0 0 0 0 0 1M
accountsPayables 7M 950 000 -4M 2M -2M -10M -3M 1M -4M -8M 5M 3M 1M -110 000
otherWorkingCapital 9M -46M 56M 14M 11M -16M 8M 2M -20M 9M -86M 9M 55M 87M
otherNonCashItems 143M 27M 51M 15M 7M 44M 25M 11M 10M 11M 60M 32M 32M 28M
netCashProvidedByOperatingActivities -108M -128M -396M -102M -99M -130M -414M -96M -122M -122M -300M -84M -143M 9M
investmentsInPropertyPlantAndEquipment -9M -4M -4M -2M -2M 2M -1M -220 000 -717 000 -402 000 -11M -6M -49M -11M
acquisitionsNet 0 0 0 0 0 0 0 -73M -83M 0 251M 0 99M 185M
purchasesOfInvestments -335M -218M -1 293M -214M -815M -143M -635M -118M -202M -90M -855M -467M -525M -436M
salesMaturitiesOfInvestments 274M 280M 744M 170M 166M 175M 876M 191M 284M 256M 605M 181M 426M 250M
otherInvestingActivites 0 -5M 2M -650M -2M 73M 83M 0 0
netCashUsedForInvestingActivites -71M 53M -45M -652M 33M 73M 82M 165M -292M
debtRepayment 324M -3M -3M -3M -932 000 -217 000 -212 000 -207 000 -141M
commonStockIssued -14M 7M -653M 613M 123M 4M 6M 0 0
commonStockRepurchased 21M 0 0 17M 0 30M 0 0 0 4M 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites -720 000 74M 6M 211M -18M 50M 0 -11M 530M
netCashUsedProvidedByFinancingActivities 330M 79M 3M 821M 104M 54M 5M -7M 389M
effectOfForexChangesOnCash 46 000 -682 000 209 000 -126 000 16 000 27 000 -20 000 -31M 34M 0 0 0 0 0
netChangeInCash 152M 2M -18M -143M 70M 7M 46M 31M -34M 36M -45M 13M 30M 47M
cashAtEndOfPeriod 229M 77M 95M 47M 191M 120M 113M 100M 69M 103M 67M 106M 113M 83M
cashAtBeginningOfPeriod 77M 74M 113M 191M 120M 113M 67M 69M 103M 67M 113M 94M 83M 36M
operatingCashFlow -108M -128M -396M -102M -99M -130M -414M -96M -122M -122M -300M -84M -143M 9M
capitalExpenditure -9M -4M -4M -2M -2M 2M -1M -220 000 -717 000 -402 000 -11M -6M -49M -11M
freeCashFlow -117M -132M -400M -104M -101M -128M -416M -96M -123M -123M -311M -90M -191M -2M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-27 2024-02-28 2023-03-01 2022-02-25 2021-02-26
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 0 0 -251M -99M -185M
netCashProvidedByInvestingActivities -553M 239M -262M -148M -197M
netDebtIssuance -10M -858 000 335M 0 0
longTermNetDebtIssuance -10M -858 000 335M 0 0
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 707M 164M 18M 312M 225M
netCommonStockIssuance 707M 164M 18M 312M 225M
commonStockIssuance 707M 164M 18M 312M 225M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 233M 58M 164M 8M 9M
netCashProvidedByFinancingActivities 931M 221M 516M 320M 234M
incomeTaxesPaid 0 0 0 0 0
interestPaid 0 10M 0 0 0

Earning call transcript

2025 q3
2025-11-06 ET (fiscal 2025 q3)
2025 q2
2025-08-08 ET (fiscal 2025 q2)
2025 q1
2025-05-07 ET (fiscal 2025 q1)
2024 q4
2025-02-27 ET (fiscal 2024 q4)
2024 q3
2024-11-06 ET (fiscal 2024 q3)
2024 q1
2024-05-09 ET (fiscal 2024 q1)
2023 q4
2024-02-27 ET (fiscal 2023 q4)
2023 q3
2023-11-03 ET (fiscal 2023 q3)
2023 q2
2023-08-03 ET (fiscal 2023 q2)
2023 q1
2023-05-04 ET (fiscal 2023 q1)
2022 q4
2023-03-01 ET (fiscal 2022 q4)
2022 q3
2022-11-06 ET (fiscal 2022 q3)
2022 q2
2022-08-07 ET (fiscal 2022 q2)
2022 q1
2022-05-04 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2026-05-27 20:00 ET
Cytokinetics to Participate in June Investor Conferences
2026-05-20 20:00 ET
Cytokinetics to Hold Annual Meeting of Stockholders
2026-05-18 20:00 ET
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2026-05-14 11:30 ET
Cytokinetics to Host Annual Symposium on Contemporary Landscapes in Muscle Biology (CLIMB)
2026-05-12 ET
Cytokinetics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
2026-05-11 ET
Cytokinetics Announces New Data Related to MYQORZO® (aficamten) at ESC Heart Failure 2026
2026-05-08 ET
Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $805 Million
2026-05-06 ET
Cytokinetics Announces Pricing of Upsized Public Offering of Common Stock
2026-05-05 ET
Cytokinetics Announces Proposed Public Offering of Common Stock
2026-05-05 ET
Cytokinetics Reports First Quarter 2026 Financial Results and Provides Business Update
2026-05-05 ET
Cytokinetics Announces Positive Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy
2026-05-04 ET
Cytokinetics to Announce Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy, on May 5, 2026
2026-04-28 ET
Cytokinetics Announces Nine Upcoming Presentations at the European Society of Cardiology Heart Failure 2026 Congress
2026-04-21 ET
Cytokinetics to Announce First Quarter Results on May 5, 2026
2026-04-20 ET
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2026-04-06 ET
Cytokinetics to Participate in the 25th Annual Needham Virtual Healthcare Conference
2026-03-18 ET
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2026-03-16 ET
Cytokinetics Announces Four Presentations at the American College of Cardiology Annual Scientific Session & Expo
2026-03-02 ET
Cytokinetics to Participate in March Investor Conferences
2026-02-24 ET
Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update
2026-02-17 12:30 ET
Cytokinetics Announces European Commission Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
2026-02-12 21:00 ET
Cytokinetics to Announce Fourth Quarter Results on February 24, 2026
2026-02-09 12:30 ET
Cytokinetics Announces Recipients of Its Eighth Annual Communications Grant Program
2026-01-27 ET
Cytokinetics and Olympic Gold Medalist Sydney McLaughlin-Levrone Team Up to Raise Awareness of the Whole-Person Impact of Hypertrophic Cardiomyopathy (HCM)
2026-01-27 ET
Cytokinetics Announces MYQORZO™ (aficamten) Now Available in the U.S. for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms
2026-01-20 ET
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-01-05 ET
Cytokinetics to Present at the 44th Annual J.P. Morgan Healthcare Conference
2025-12-19 ET
Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms
2025-12-17 ET
Cytokinetics Announces NMPA Approval of MYQORZO® (aficamten) in China for Patients with Obstructive Hypertrophic Cardiomyopathy
2025-12-16 ET
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2025-12-12 ET
Cytokinetics Announces Positive CHMP Opinion of MYQORZO® (Aficamten) for the Treatment of Obstructive Hypertrophic Cardiomyopathy
2025-11-18 ET
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2025-11-17 ET
Cytokinetics Supports American Heart Association Initiative to Improve Care for People Living With Hypertrophic Cardiomyopathy
2025-11-17 ET
Expanded Effort Will Help Standardize, Improve Care for Hypertrophic Cardiomyopathy
2025-11-14 ET
Investors SueWallSt as Cytokinetics, Incorporated Faces Securities Fraud Allegations
2025-11-13 ET
Investors SueWallSt as Cytokinetics, Incorporated Faces Securities Fraud Allegations
2025-11-10 ET
Investors SueWallSt as Cytokinetics, Incorporated Faces Securities Fraud Allegations
2025-11-10 ET
Cytokinetics Presents Additional Data from MAPLE-HCM at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025
2025-11-05 ET
Cytokinetics Reports Third Quarter 2025 Financial Results and Provides Business Update
2025-11-05 ET
Investors SueWallSt as Cytokinetics, Incorporated Faces Securities Fraud Allegations
2025-11-04 ET
Cytokinetics to Participate in November Investor Conferences
2025-10-31 ET
Cytokinetics Announces Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025
2025-10-30 ET
Investors SueWallSt as Cytokinetics, Incorporated Faces Securities Fraud Allegations
2025-10-22 ET
Cytokinetics to Announce Third Quarter Results on November 5, 2025
2025-10-20 ET
Shareholders SueWallSt in New Class Action Against Cytokinetics, Incorporated - Act Now
2025-10-17 ET
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2025-10-01 ET
Shareholders SueWallSt in New Class Action Against Cytokinetics, Incorporated - Act Now
2025-09-30 ET
Shareholders SueWallSt in New Class Action Against Cytokinetics, Incorporated - Act Now
2025-09-29 ET
Cytokinetics Presents New Data Related to Aficamten at the HFSA Annual Scientific Meeting 2025
2025-09-24 ET
Cytokinetics Announces Call for Proposals for Its Eighth Annual Communications Grant Program
2025-09-23 ET
Cytokinetics to Present at the Stifel 2025 Virtual Cardiometabolic Forum
2025-09-18 ET
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2025-09-18 ET
Cytokinetics Announces Three Upcoming Presentations at the HFSA Annual Scientific Meeting 2025
2025-09-16 ET
Cytokinetics Announces Pricing of Upsized $650.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2027 Convertible Notes
2025-09-16 ET
Cytokinetics Announces Proposed Private Placement of $550.0 Million of Convertible Senior Notes
2025-08-31 ET
Cytokinetics Presents New Data Related to Aficamten at the European Society of Cardiology Congress 2025
2025-08-30 ET
Cytokinetics Announces Primary Results from MAPLE-HCM Presented at the European Society of Cardiology Congress 2025 and Published in The New England Journal Of Medicine
2025-08-27 ET
Cytokinetics to Participate in September Investor Conferences
2025-08-25 ET
Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2025
2025-08-20 ET
Cytokinetics Names Jim Daly to Board of Directors
2025-08-19 ET
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-08-07 ET
Cytokinetics Reports Second Quarter 2025 Financial Results and Provides Business Update
2025-07-24 ET
Cytokinetics to Announce Second Quarter Results On August 7, 2025
2025-07-18 ET
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2025-07-10 ET
Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2025
2025-06-17 ET
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-06-10 ET
Cytokinetics Announces Call For Proposals For Annual Corporate Giving Program
2025-05-29 ET
Cytokinetics to Participate in the Jefferies Global Healthcare Conference
2025-05-18 ET
Cytokinetics Presents Additional Data Related to Aficamten at the European Society of Cardiology Heart Failure 2025 Congress
2025-05-16 ET
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-05-15 ET
Cytokinetics to Host Symposium on Contemporary Landscapes in Muscle Biology
2025-05-13 ET
Cytokinetics Announces Positive Topline Results From MAPLE-HCM
2025-05-08 ET
Cytokinetics Announces Four Upcoming Presentations at the European Society Of Cardiology Heart Failure 2025 Congress
2025-05-07 ET
Cytokinetics to Hold Annual Meeting of Stockholders
2025-05-06 ET
Cytokinetics Reports First Quarter 2025 Financial Results and Provides Business Update
2025-05-01 ET
Cytokinetics Announces New PDUFA Date for Aficamten in Obstructive Hypertrophic Cardiomyopathy
2025-04-30 ET
Cytokinetics to Participate in May Investor Conferences
2025-04-22 ET
Cytokinetics to Announce First Quarter Results on May 6, 2025
2025-04-17 ET
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-03-31 ET
Cytokinetics to Participate in the 24th Annual Needham Virtual Healthcare Conference
2025-03-20 ET
Cytokinetics Announces Launch of EARTH-HCM, a Public Health Education Tool for the Hypertrophic Cardiomyopathy Community
2025-03-18 ET
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-03-17 ET
Cytokinetics Announces Five Presentations at the American College of Cardiology Annual Scientific Session & Expo
2025-03-03 ET
Cytokinetics to Participate in March Investor Conferences
2025-02-27 ET
Cytokinetics Reports Fourth Quarter 2024 Financial Results and Provides Business Update
2025-02-19 ET
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-02-13 ET
Cytokinetics to Announce Fourth Quarter Results on February 27, 2025
2025-02-11 ET
Cytokinetics Names Robert E. Landry to Board of Directors
2025-02-05 ET
Cytokinetics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
2025-02-04 ET
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-01-30 ET
Cytokinetics Announces Recipients of Its Seventh Annual Communications Grant Program
2025-01-21 ET
Cytokinetics Announces Start of AMBER-HFpEF, a Phase 2 Clinical Trial of CK-586 in Patients With Symptomatic Heart Failure With Preserved Ejection Fraction
2025-01-13 ET
Cytokinetics Announces 2025 Corporate Milestones and Vision 2030
2025-01-06 ET
Cytokinetics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
2025-01-03 ET
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2024-12-23 ET
Cytokinetics Announces European Medicines Agency Validation of Marketing Authorization Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy
2024-12-20 ET
Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China
2024-12-03 ET
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-12-03 ET
Cytokinetics Announces Start of COMET-HF, a Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Symptomatic Heart Failure with Severely Reduced Ejection Fraction
2024-12-02 ET
Cytokinetics to Participate in December Investor Conferences
2024-12-02 ET
Cytokinetics Announces FDA Acceptance of New Drug Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy
2024-11-19 ET
Cytokinetics and Bayer Announce Exclusive Licensing Collaboration for Aficamten in Japan
2024-11-12 ET
Cytokinetics to Participate in the 2024 Jefferies London Healthcare Conference
2024-11-11 ET
Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-4015089
2024-11-06 21:00 ET
Cytokinetics Reports Third Quarter 2024 Financial Results
2024-11-05 21:00 ET
Cytokinetics Announces Six Upcoming Presentations at the American Heart Association Scientific Sessions 2024
2024-11-04 21:00 ET
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-10-23 20:00 ET
Cytokinetics to Announce Third Quarter Results on November 6, 2024
2024-10-16 11:30 ET
Cytokinetics Highlights Progress in Cardiac Myosin Modulation Programs and Global Commercial Launch Readiness at Investor & Analyst Day
2024-10-03 20:00 ET
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-10-02 20:00 ET
Cytokinetics to Host Investor & Analyst Day on October 16, 2024
2024-09-30 13:20 ET
Cytokinetics Presents Additional Data From SEQUOIA-HCM at the HFSA Annual Scientific Meeting
2024-09-27 15:00 ET
Cytokinetics Presents Additional Data from SEQUOIA-HCM at the HCMS Scientific Sessions
2024-09-24 11:30 ET
Cytokinetics Announces Call for Proposals for Its Seventh Annual Communications Grant Program
2024-09-19 20:00 ET
Cytokinetics Announces Upcoming Presentations at the HCMS Scientific Sessions and the HFSA Annual Scientific Meeting
2024-09-09 11:30 ET
Cytokinetics Announces Data From Phase 1 Study of CK-4021586
2024-09-05 20:00 ET
Cytokinetics Announces Two Presentations at the 2024 American College of Clinical Pharmacology Annual Meeting
2024-09-04 20:00 ET
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-09-01 08:27 ET
Cytokinetics Presents New Data Related to the Safety and Long-Term Use of Aficamten at the European Society of Cardiology Congress 2024
2024-09-01 07:51 ET
Cytokinetics Presents Additional Data From SEQUOIA-HCM at the European Society of Cardiology Congress 2024
2024-08-29 20:00 ET
Cytokinetics to Participate in September Investor Conferences
2024-08-08 20:00 ET
Cytokinetics Reports Second Quarter 2024 Financial Results
2024-08-01 20:00 ET
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2024-07-30 11:30 ET
Cytokinetics Announces Call for Proposals for Corporate Giving Program
2024-07-25 20:00 ET
Cytokinetics to Announce Second Quarter Results on August 8, 2024
2024-07-16 11:30 ET
Cytokinetics Announces Seven Upcoming Presentations at the European Society of Cardiology Congress 2024
2024-07-03 20:00 ET
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2024-06-17 11:30 ET
Cytokinetics Announces Initiation of Phase 1 Study of Aficamten in Healthy Japanese Participants
2024-06-04 20:00 ET
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-05-29 20:00 ET
Cytokinetics to Participate in June Investor Conferences
2024-05-28 20:00 ET
Cytokinetics Announces Closing of Public Offering of Common Stock
2024-05-23 03:30 ET
Cytokinetics Announces Pricing of Public Offering of Common Stock
2024-05-22 20:02 ET
Cytokinetics Announces Proposed Public Offering of Common Stock
2024-05-22 20:00 ET
Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
2024-05-17 11:30 ET
Cytokinetics Hosts Muscle Biology-Focused Research Symposium: Contemporary Landscapes in Muscle Biology
2024-05-15 11:30 ET
Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2024
2024-05-13 13:33 ET
Cytokinetics Announces Primary Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress and Published in the New England Journal of Medicine
2024-05-13 13:33 ET
Cytokinetics Announces Additional Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress
2024-05-08 20:00 ET
Cytokinetics Reports First Quarter 2024 Financial Results
2024-05-08 11:30 ET
Cytokinetics Announces Start of CEDAR-HCM, a Clinical Trial of Aficamten in a Pediatric Population With Symptomatic Obstructive Hypertrophic Cardiomyopathy
2024-05-08 11:30 ET
Cytokinetics Announces Topline Data From Phase 1 Clinical Study of CK-4021586
2024-05-07 20:00 ET
Cytokinetics to Hold Annual Meeting of Stockholders
2024-05-02 20:00 ET
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-04-29 20:00 ET
Cytokinetics to Host Investor Event and Conference Call to Discuss the Primary Results From SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress
2024-04-24 20:00 ET
Cytokinetics to Announce First Quarter Results on May 8, 2024
2024-04-10 11:30 ET
Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress
2024-04-05 11:30 ET
Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Study of Aficamten, at The American College of Cardiology 73ʳᵈ Annual Scientific Session
2024-04-02 20:00 ET
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-04-01 20:00 ET
Cytokinetics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
2024-03-25 12:15 ET
Cytokinetics Announces Four Upcoming Presentations at the American College of Cardiology 73rd Annual Scientific Session
2024-03-04 21:00 ET
Cytokinetics to Participate in March Investor Conferences
2024-03-01 21:00 ET
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-02-29 12:30 ET
Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day
2024-02-28 12:30 ET
Cytokinetics, The Mended Hearts, Inc. and WomenHeart Announce Launch of New Initiative to Increase Engagement in Cardiovascular Clinical Trials
2024-02-27 21:00 ET
Cytokinetics Reports Fourth Quarter 2023 Financial Results
2024-02-13 21:00 ET
Cytokinetics to Announce Fourth Quarter Results on February 27, 2024
2024-02-06 21:00 ET
Cytokinetics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
2024-01-29 12:30 ET
Cytokinetics Announces Recipients of Its Sixth Annual Communications Grant Program
2024-01-25 12:30 ET
Cytokinetics Presents New Data at CMR 2024 From FOREST-HCM, the Open Label Extension Clinical Trial of Aficamten
2024-01-18 18:00 ET
Cytokinetics Announces New Data From FOREST-HCM to be Presented at CMR 2024
2024-01-03 21:00 ET
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-01-02 21:00 ET
Cytokinetics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-27 12:30 ET
Cytokinetics Announces Positive Results From SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy
2023-12-26 21:00 ET
Cytokinetics to Host Investor Call on December 27 to Discuss the Topline Results from SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy
2023-12-07 12:30 ET
Cytokinetics Presents Results From COURAGE-ALS at the 34th International Symposium on ALS/MND
2023-12-01 21:00 ET
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-11-29 21:00 ET
Cytokinetics Announces Five Presentations at the 34th International Symposium on ALS/MND
2023-11-03 20:00 ET
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2023-11-02 20:00 ET
Cytokinetics Reports Third Quarter 2023 Financial Results
2023-11-01 20:00 ET
Cytokinetics to Participate in Upcoming Investor Conferences
2023-10-23 20:00 ET
Cytokinetics to Announce Third Quarter Results on November 2, 2023
2023-10-19 11:30 ET
Cytokinetics Provides Update on Cardiac Myosin Inhibitor Programs and Plans to Build a Specialty Cardiology Franchise at Virtual Investor & Analyst Day
2023-10-06 16:45 ET
Cytokinetics Presents Baseline Characteristics From SEQUOIA-HCM at the HCM Society Scientific Sessions
2023-10-05 20:00 ET
Cytokinetics to Host Virtual Investor & Analyst Day on October 19, 2023
2023-10-03 20:00 ET
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2023-10-02 20:00 ET
Cytokinetics Announces Upcoming Presentations at the 2023 HCMS Scientific Sessions and the HFSA Annual Scientific Meeting
2023-09-28 11:30 ET
Cytokinetics Announces Call for Proposals for Its Sixth Annual Communications Grant Program
2023-09-07 20:00 ET
Cytokinetics to Participate in Upcoming Investor Conferences
2023-09-06 11:30 ET
Cytokinetics Announces Start of ACACIA-HCM, a Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
2023-09-01 20:00 ET
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-08-03 20:00 ET
Cytokinetics Reports Second Quarter 2023 Financial Results
2023-08-01 20:00 ET
Cytokinetics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
2023-07-27 20:00 ET
Cytokinetics to Announce Second Quarter Results on August 3, 2023
2023-07-05 20:00 ET
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-06-20 11:30 ET
Cytokinetics Announces Start of MAPLE-HCM, a Phase 3 Clinical Trial of Aficamten Compared to Metoprolol in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
2023-06-02 20:00 ET
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2023-06-01 20:00 ET
Cytokinetics to Participate in Upcoming Investor Conferences
2023-05-20 14:30 ET
Cytokinetics Presents New Data in Patients With Non-Obstructive HCM From Cohort 4 of REDWOOD-HCM in Late-Breaking Clinical Trial Session at The European Society of Cardiology Heart Failure 2023 Congress
2023-05-15 20:00 ET
Cytokinetics Announces Three Upcoming Presentations at the European Society of Cardiology Heart Failure 2023 Congress
2023-05-11 11:30 ET
Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-4021586
2023-05-08 20:00 ET
Cytokinetics to Participate in the JMP Securities Life Sciences Conference
2023-05-04 20:00 ET
Cytokinetics Reports First Quarter 2023 Financial Results
2023-05-03 20:00 ET
Cytokinetics to Hold Annual Meeting of Stockholders
2023-05-01 20:00 ET
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-04-20 20:00 ET
Cytokinetics to Announce First Quarter Results on May 4, 2023
2023-04-10 20:00 ET
Cytokinetics To Participate In The 22nd Annual Needham Virtual Healthcare Conference
2023-04-03 20:00 ET
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-03-31 11:30 ET
Cytokinetics Announces COURAGE-ALS Met Criteria for Futility at Second Interim Analysis
2023-03-27 11:30 ET
Cytokinetics Releases Inaugural Corporate Responsibility Report
2023-03-06 21:00 ET
Cytokinetics to Participate in Upcoming Investor Conferences
2023-03-04 15:00 ET
Cytokinetics Presents Positive Results From Cohort 4 of REDWOOD-HCM and Long-Term Results From FOREST-HCM at the American College of Cardiology 72nd Annual Scientific Session
2023-03-02 21:00 ET
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-03-01 21:00 ET
Cytokinetics Reports Fourth Quarter 2022 Financial Results
2023-02-28 22:31 ET
Cytokinetics Receives Complete Response Letter From FDA for New Drug Application for Omecamtiv Mecarbil
2023-02-24 21:00 ET
Cytokinetics Announces Three Upcoming Presentations at the American College of Cardiology 72nd Annual Scientific Session
2023-02-22 12:30 ET
Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day
2023-02-15 21:00 ET
Cytokinetics to Announce Fourth Quarter Results on March 1, 2023
2023-02-01 21:00 ET
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-01-30 12:30 ET
Cytokinetics Announces Recipients of Its Fifth Annual Communications Grant Program
2023-01-04 21:00 ET
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-01-03 21:00 ET
Cytokinetics to Participate in the 41st Annual J.P. Morgan Healthcare Conference
2022-12-13 22:45 ET
Cytokinetics Announces Outcome of FDA Advisory Committee Vote On Omecamtiv Mecarbil
2022-12-13 12:02 ET
Cytokinetics Stock Trading Halted Today
2022-12-09 13:59 ET
Cytokinetics Announces Availability of Briefing Documents for FDA Advisory Committee Meeting on Omecamtiv Mecarbil
2022-12-08 12:30 ET
Cytokinetics Presents Data at the Virtual 33rd International Symposium on ALS/MND
2022-12-07 12:30 ET
Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-3828136
2022-12-02 21:00 ET
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-12-01 21:00 ET
Cytokinetics Announces Presentation at the Virtual 33rd International Symposium on ALS/MND
2022-11-07 12:30 ET
Cytokinetics Presents New Data at the American Heart Association Scientific Sessions 2022
2022-11-03 20:00 ET
Cytokinetics Reports Third Quarter 2022 Financial Results
2022-11-01 20:00 ET
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-10-31 11:30 ET
Cytokinetics Announces Three Upcoming Presentations at the American Heart Association Scientific Sessions 2022
2022-10-20 20:00 ET
Cytokinetics to Announce Third Quarter Results on November 3, 2022
2022-10-10 11:30 ET
Cytokinetics Announces Continuation of COURAGE-ALS Following First Interim Analysis
2022-10-03 20:00 ET
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-10-02 13:45 ET
Cytokinetics Presents New Data From REDWOOD-HCM OLE in Late Breaking Clinical Trial Session at the HFSA Annual Scientific Meeting
2022-09-30 14:30 ET
Cytokinetics Presents New Data From REDWOOD-HCM OLE in Late Breaking Clinical Trial Session at the HCM Society Scientific Sessions
2022-09-28 11:30 ET
Cytokinetics Announces Call for Proposals for Its Fifth Annual Communications Grant Program
2022-09-26 11:30 ET
Cytokinetics Announces Upcoming Presentations at the 2022 Inaugural HCM Society Scientific Sessions and the HFSA Annual Scientific Meeting
2022-09-06 20:00 ET
Cytokinetics to Participate in Upcoming Investor Conferences
2022-09-01 20:00 ET
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-08-04 20:00 ET
Cytokinetics Reports Second Quarter 2022 Financial Results
2022-08-04 11:30 ET
Cytokinetics and The ALS Association Announce Release of Updated PRO-ACT Database Including Data From Cytokinetics’ Completed ALS Clinical Trials
2022-08-01 20:00 ET
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-07-21 20:00 ET
Cytokinetics to Announce Second Quarter Results on August 4, 2022
2022-07-05 20:00 ET
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2022-07-01 07:35 ET
Cytokinetics Announces Pricing of $450 Million Convertible Senior Notes Offering
2022-06-29 20:35 ET
Cytokinetics Announces Proposed Convertible Senior Notes Offering
2022-06-24 11:30 ET
Cytokinetics Announces Date for FDA Advisory Committee Meeting to Review New Drug Application for Omecamtiv Mecarbil
2022-06-17 11:30 ET
Cytokinetics Provides Regulatory Update for Omecamtiv Mecarbil
2022-06-16 11:30 ET
Cytokinetics Announces Start of Open-Label Extension Study for Patients Completing COURAGE-ALS
2022-06-13 11:30 ET
Cytokinetics Announces Additional Data From REDWOOD-HCM Presented at the American Society of Echocardiography 33rd Annual Scientific Sessions
2022-06-03 20:00 ET
Cytokinetics Announces Additional Results From REDWOOD-HCM to Be Presented at the American Society of Echocardiography 33rd Annual Scientific Sessions
2022-06-02 20:00 ET
Cytokinetics to Participate in Upcoming Investor Conferences
2022-06-01 20:00 ET
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-05-23 15:30 ET
Cytokinetics Announces Data From REDWOOD-HCM OLE and GALACTIC-HF Presented as Late Breaking Science Presentations at the European Society of Cardiology Heart Failure 2022 Congress
2022-05-18 11:30 ET
Cytokinetics and the ALS Association Renew Partnership to Advance the Fight Against ALS
2022-05-17 20:00 ET
Cytokinetics to Participate in the 2022 H.C. Wainwright Global Life Sciences Conference
2022-05-17 11:30 ET
Cytokinetics Provides Regulatory Update Related to New Drug Application for Omecamtiv Mecarbil
2022-05-16 20:00 ET
Cytokinetics Announces Three Upcoming Presentations at the European Society of Cardiology Heart Failure 2022 Congress
2022-05-04 20:00 ET
Cytokinetics Reports First Quarter 2022 Financial Results
2022-05-03 20:00 ET
Cytokinetics to Hold Annual Meeting of Stockholders
2022-04-20 20:00 ET
Cytokinetics to Announce First Quarter Results on May 4, 2022
2022-04-08 11:30 ET
Cytokinetics Announces Changes to Board of Directors
2022-04-06 20:00 ET
Cytokinetics to Participate in the 21st Annual Needham Virtual Healthcare Conference
2022-04-03 13:45 ET
Cytokinetics Announces Results From METEORIC-HF and Additional Data From GALACTIC-HF Presented at the American College of Cardiology 71st Annual Scientific Session
2022-04-02 15:30 ET
Cytokinetics Announces Results From Cohort 3 of Redwood-HCM Presented at American College of Cardiology 71st Annual Scientific Session
2022-04-01 20:00 ET
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-03-24 20:00 ET
Cytokinetics Announces Four Upcoming Presentations at the American College of Cardiology 71st Annual Scientific Session & Expo
2022-03-08 21:00 ET
Cytokinetics to Participate in Upcoming Investor Conferences
2022-03-02 12:30 ET
Cytokinetics Announces Cohort 4 of REDWOOD-HCM Is Open to Enrollment
2022-03-01 21:00 ET
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2022-02-28 12:30 ET
Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day
2022-02-24 21:00 ET
Cytokinetics Reports Fourth Quarter 2021 Financial Results
2022-02-23 12:30 ET
Cytokinetics Announces Start of SEQUOIA-HCM, a Phase 3 Clinical Trial of Aficamten in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
2022-02-16 12:30 ET
Cytokinetics and the American Heart Association Bay Area Announce a Three-Year Collaboration to Advance Education and Awareness of Heart Disease
2022-02-15 12:30 ET
Cytokinetics Announces Topline Results From METEORIC-HF
2022-02-10 21:00 ET
Cytokinetics to Announce Fourth Quarter Results on February 24, 2022
2022-02-04 12:30 ET
Cytokinetics Announces FDA Acceptance of New Drug Application for Omecamtiv Mecarbil for the Treatment of Heart Failure With Reduced Ejection Fraction
2022-02-01 21:00 ET
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-02-01 12:30 ET
Cytokinetics Announces Positive Topline Results from Cohort 3 of REDWOOD-HCM
2022-01-24 12:30 ET
Cytokinetics Announces Recipients of Fourth Annual Communications Fellowship Grants
2022-01-10 22:00 ET
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-01-07 13:07 ET
Royalty Pharma and Cytokinetics Announce Funding Agreements Totaling up to $450 Million
2022-01-07 12:30 ET
Cytokinetics and Royalty Pharma Announce Funding Agreements Totaling up to $450 Million
2022-01-03 21:00 ET
Cytokinetics to Participate in the 40th Annual J.P. Morgan Healthcare Conference
2021-12-20 12:30 ET
Cytokinetics and JI XING Announce Expansion of Collaboration to Include Licensing of Omecamtiv Mecarbil in China; RTW to Add to Its Investment in Cytokinetics
2021-12-10 12:30 ET
Cytokinetics Announces Data From Its ALS Program Presented at the 32nd International Symposium on ALS/MND
2021-12-09 12:30 ET
Cytokinetics Announces Receipt of Breakthrough Therapy Designation from FDA for Aficamten
2021-12-01 21:00 ET
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-11-30 21:00 ET
Cytokinetics Announces Four Presentations at the 32nd International Symposium on ALS/MND
2021-11-15 21:00 ET
Cytokinetics to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
2021-11-15 12:30 ET
Cytokinetics Announces Additional Results from GALACTIC-HF Presented at American Heart Association Scientific Sessions 2021  
2021-11-08 21:00 ET
Cytokinetics Announces Two Presentations at the AHA Scientific Sessions 2021
2021-11-03 20:00 ET
Cytokinetics Reports Third Quarter 2021 Financial Results
2021-11-01 20:00 ET
Cytokinetics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
2021-10-29 11:30 ET
Cytokinetics Announces Preclinical Data Relating to CK-3828136 Presented at the 2021 Medicinal Chemistry Gordon Research Conference
2021-10-21 20:00 ET
Cytokinetics Announces Preclinical Data for CK-3828136 to Be Presented at the 2021 Medicinal Chemistry Gordon Research Conference
2021-10-20 20:00 ET
Cytokinetics to Announce Third Quarter Results on November 3, 2021
2021-10-07 11:30 ET
Cytokinetics Outlines Go-To-Market Strategy for Omecamtiv Mecarbil and Provides Updates on Cardiovascular Pipeline at Today’s Analyst & Investor Day
2021-10-01 20:00 ET
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-09-28 11:30 ET
Cytokinetics Announces Fourth Annual Communications Fellowship Grant Program Call for Proposals
2021-09-23 20:00 ET
Cytokinetics to Host Analyst & Investor Day on October 7, 2021
2021-09-12 15:45 ET
Cytokinetics Announces Results From REDWOOD-HCM and GALACTIC-HF Presented in Late Breaking Clinical Trial Session at the HFSA Annual Scientific Meeting
2021-09-08 20:00 ET
Cytokinetics to Participate in September Investor Conferences
2021-09-07 11:30 ET
Cytokinetics to Host Investor Call and Webcast to Discuss the Full Results From Redwood-HCM at the HFSA Annual Scientific Meeting
2021-09-01 20:00 ET
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-08-31 11:30 ET
Cytokinetics Announces Results From REDWOOD-HCM and GALACTIC-HF to Be Presented in Late Breaking Clinical Trials Session at the HFSA Annual Scientific Meeting
2021-08-19 11:30 ET
Cytokinetics and Cure SMA Renew Partnership to Advance Education and Awareness of SMA
2021-08-05 20:00 ET
Cytokinetics Reports Second Quarter 2021 Financial Results
2021-08-02 20:00 ET
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-08-02 11:30 ET
Cytokinetics Announces Start of COURAGE-ALS, a Phase 3 Clinical Trial of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis
2021-07-23 16:45 ET
Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
2021-07-22 20:00 ET
Cytokinetics to Announce Second Quarter Results on August 5, 2021
2021-07-21 03:15 ET
Cytokinetics Announces Pricing of Public Offering of Common Stock
2021-07-19 20:00 ET
Cytokinetics Announces Proposed Public Offering of Common Stock
2021-07-19 11:36 ET
Cytokinetics Announces Positive Topline Results of Redwood-HCM
2021-07-01 20:00 ET
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-06-30 11:30 ET
Cytokinetics Announces Additional Results From GALACTIC-HF Presented at the European Society of Cardiology Heart Failure 2021
2021-06-23 11:30 ET
Cytokinetics Announces Three Presentations to Occur at the European Society of Cardiology Heart Failure 2021 Congress
2021-06-15 11:30 ET
Cytokinetics Announces Completion of Enrollment in METEORIC-HF, The Second Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure With Reduced Ejection Fraction
2021-06-02 20:00 ET
Cytokinetics to Participate in Upcoming Investor Conferences
2021-06-01 20:00 ET
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-05-19 11:30 ET
Cytokinetics and The ALS Association Renew Partnership to Advance the Fight Against ALS
2021-05-17 12:00 ET
Cytokinetics Announces Secondary Analysis of GALACTIC-HF Presented in Late Breaking Clinical Trial Session at the American College of Cardiology 70th Annual Scientific Session and Published in the Journal of American College of Cardiology
2021-05-16 12:00 ET
Cytokinetics Announces Presentations Related to Health Economics and Outcomes Research in Heart Failure and Hypertrophic Cardiomyopathy at American College of Cardiology 70th Annual Scientific Session & Expo (ACC.21)
2021-05-10 20:00 ET
Cytokinetics Announces Three Upcoming Presentations Related to Heart Failure and Hypertrophic Cardiomyopathy at American College of Cardiology 70th Annual Scientific Session
2021-05-06 20:00 ET
Cytokinetics Reports First Quarter 2021 Financial Results
2021-05-06 11:30 ET
Cytokinetics Announces Start of Open-Label Extension Study for Patients Completing REDWOOD-HCM
2021-05-05 20:00 ET
Cytokinetics to Hold Annual Meeting of Stockholders
2021-05-04 11:30 ET
Cytokinetics Announces Cohort 3 of REDWOOD-HCM is Open to Enrollment
2021-05-03 20:00 ET
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-04-22 20:00 ET
Cytokinetics to Announce First Quarter Results on May 6, 2021
2021-04-12 11:30 ET
Cytokinetics Announces Preclinical Data for CK-3773274 Presented at the American Chemical Society Spring 2021 Virtual Meeting
2021-04-05 20:00 ET
Cytokinetics to Participate in the 20th Annual Needham Virtual Healthcare Conference
2021-04-02 20:00 ET
Cytokinetics Announces Preclinical Data for CK-3773274 to be Presented at the American Chemical Society Spring 2021 Virtual Meeting
2021-04-01 20:00 ET
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-03-18 11:30 ET
Cytokinetics Announces Secondary Analysis From GALACTIC-HF to Be Presented in Late Breaking Clinical Trial Session at American College of Cardiology 70th Annual Scientific Session & Expo (ACC.21)
2021-03-02 21:00 ET
Cytokinetics to Participate in Upcoming Investor Conferences
2021-02-26 21:32 ET
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-02-26 12:30 ET
Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day
2021-02-25 21:00 ET
Cytokinetics Reports Fourth Quarter 2020 Financial Results
2021-02-18 12:30 ET
Cytokinetics Names Muna Bhanji to Board of Directors
2021-02-11 21:00 ET
Cytokinetics to Announce Fourth Quarter Results on February 25, 2021
2021-02-02 12:30 ET
Cytokinetics Announces Recipients of Third Annual Communications Fellowship Grants
2021-02-01 21:00 ET
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-01-13 12:30 ET
Cytokinetics Announces First Patient Dosed in Cohort 2 of Redwood-HCM
2021-01-11 12:30 ET
Cytokinetics Granted Orphan Drug Designation for CK-3773274 for the Treatment of Hypertrophic Cardiomyopathy
2021-01-06 21:00 ET
Cytokinetics to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference
2020-12-23 12:30 ET
Cytokinetics Regains European Rights to Omecamtiv Mecarbil
2020-12-14 12:30 ET
Cytokinetics Announces Data and Trial Design Presented at the International Symposium on ALS/MND
2020-12-09 12:30 ET
Cytokinetics Announces Progression of REDWOOD-HCM to Cohort 2
2020-12-07 12:30 ET
Cytokinetics Announces Additional Results From GALACTIC-HF Presented at the 17th Global Cardiovascular Clinical Trialists
2020-12-03 12:30 ET
Cytokinetics Announces Three Presentations at the International Symposium on ALS/MND
2020-12-01 21:00 ET
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2020-12-01 12:30 ET
Cytokinetics Announces Additional Results From GALACTIC-HF to be Presented at the 17th Global Cardiovascular Clinical Trialists Forum
2020-11-24 21:00 ET
Cytokinetics to Participate in Upcoming Investor Conferences
2020-11-23 12:30 ET
Cytokinetics Regains Rights to Develop and Commercialize Omecamtiv Mecarbil and AMG 594 From Amgen
2020-11-20 12:30 ET
Cytokinetics Names Nancy Wysenski to Board of Directors
2020-11-16 12:30 ET
Cytokinetics Announces Presentations Related to Health Economics and Outcomes Research in Heart Failure and Hypertrophic Cardiomyopathy at the AHA Scientific Sessions 2020
2020-11-16 12:30 ET
Cytokinetics Announces Preclinical Data for CK-3773274 and CK-3772271 Presented at the AHA Scientific Sessions 2020
2020-11-13 16:35 ET
Cytokinetics Announces Results From GALACTIC-HF Presented at Late Breaking Clinical Trial Session at the American Heart Association Scientific Sessions and Published in the New England Journal of Medicine
2020-11-10 21:00 ET
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-11-06 12:30 ET
Cytokinetics Announces Six Presentations Related to Heart Failure and Hypertrophic Cardiomyopathy at the AHA Scientific Sessions 2020
2020-11-04 21:00 ET
Cytokinetics Reports Third Quarter 2020 Financial Results
2020-10-21 20:00 ET
Cytokinetics to Announce Third Quarter Results on November 4, 2020
2020-10-08 12:30 ET
Amgen, Cytokinetics and Servier Announce Topline Results From GALACTIC-HF, a Phase 3 Trial of Omecamtiv Mecarbil in Patients With Heart Failure
2020-10-08 12:30 ET
Amgen, Cytokinetics And Servier Announce Topline Results From GALACTIC-HF, A Phase 3 Trial Of Omecamtiv Mecarbil In Patients With Heart Failure
2020-10-05 20:00 ET
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-10-05 11:30 ET
Cytokinetics Announces Data From Two Presentations at the HFSA Virtual Annual Scientific Meeting 2020
2020-10-02 11:30 ET
Cytokinetics Announces Publication of Manuscript Detailing Baseline Characteristics of GALACTIC-HF in European Journal of Heart Failure
2020-09-24 20:00 ET
Cytokinetics Announces Data to Be Presented at the HFSA Virtual Annual Scientific Meeting 2020
2020-09-24 11:30 ET
Cytokinetics Announces Third Annual Communications Fellowship Program Call for Proposals
2020-09-23 11:30 ET
Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-3772271
2020-09-17 11:30 ET
Cytokinetics Announces GALACTIC-HF Accepted for Presentation In Late Breaking Clinical Trial Session At American Heart Association Scientific Sessions
2020-09-02 20:00 ET
Cytokinetics to Participate in Upcoming Investor Conferences
2020-08-26 11:30 ET
Cytokinetics and Cure SMA Renew Partnership to Advance Education and Awareness of SMA
2020-08-18 11:30 ET
Cytokinetics Announces Partnership to Improve Prediction of Risk and Outcomes in Hypertrophic Cardiomyopathy
2020-08-06 20:00 ET
Cytokinetics Reports Second Quarter 2020 Financial Results
2020-07-23 20:00 ET
Cytokinetics to Announce Second Quarter Results on August 6, 2020
2020-07-21 20:00 ET
Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
2020-07-17 03:32 ET
Cytokinetics Announces Pricing of Public Offering of Common Stock
2020-07-15 20:00 ET
Cytokinetics Announces Proposed Public Offering of Common Stock
2020-07-15 11:30 ET
Cytokinetics Provides Updates on Its Cardiovascular Pipeline and Strategies to Build a Commercial Franchise at Today’s Virtual Investor & Analyst Day
2020-07-14 11:30 ET
Cytokinetics Announces Licensing Collaboration and Royalty Monetization Deals with RTW Investments Focused to CK-3773274, Next-Generation Cardiac Myosin Inhibitor
2020-07-13 11:30 ET
Cytokinetics Announces Participation in the Launch of Kainomyx, Inc. Focused to the Treatment of Parasitic Diseases
2020-07-01 20:00 ET
Cytokinetics to Host Virtual Investor & Analyst Day on July 15, 2020
2020-06-08 20:00 ET
Cytokinetics to Participate In Upcoming Investor Conferences
2020-05-27 11:30 ET
Cytokinetics and The ALS Association Renew Partnership to Advance the Fight Against ALS
2020-05-08 12:30 ET
FDA Grants Fast Track Designation for Omecamtiv Mecarbil in Heart Failure
2020-05-07 20:00 ET
Cytokinetics to Hold Annual Meeting of Stockholders
2020-05-06 20:00 ET
Cytokinetics Reports First Quarter 2020 Financial Results
2020-04-22 20:00 ET
Cytokinetics to Announce First Quarter Results on May 6, 2020
2020-04-14 11:30 ET
Cytokinetics Provides Clinical Trials and Business Update in Response to COVID-19 Pandemic
2020-04-08 20:00 ET
Cytokinetics to Participate in the 19th Annual Needham Virtual Healthcare Conference
2020-03-30 11:30 ET
Cytokinetics Announces Baseline Characteristics from GALACTIC-HF at ACC.20/WCC Virtual
2020-03-20 20:00 ET
CYTOKINETICS TO ANNOUNCE BASELINE CHARACTERISTICS FROM GALACTIC-HF DURING ACC.20/WCC
2020-03-04 12:30 ET
Cytokinetics Granted European Orphan Designation for Reldesemtiv for the Treatment of Amyotrophic Lateral Sclerosis
2020-03-03 21:00 ET
Cytokinetics Reports Fourth Quarter 2019 Financial Results
2020-03-03 12:30 ET
Cytokinetics Announces Preclinical Data for AMG 594 Presented at the Keystone Symposium on Heart Failure
2020-02-28 12:30 ET
Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day
2020-02-26 13:30 ET
Amgen, Cytokinetics and Servier Announce Continuation of GALACTIC-HF Following Planned Interim Analysis
2020-02-20 12:30 ET
Cytokinetics Announces Preclinical Data for CK-3773274 Presented at the Biophysical Society 64th Annual Meeting
2020-02-18 21:00 ET
Cytokinetics to Announce Fourth Quarter Results on March 3, 2020
2020-02-06 09:30 ET
Cytokinetics Announces Publication Relating to Design of GALACTIC-HF, a Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure
2020-01-22 12:30 ET
Cytokinetics Announces Recipients of Second Annual Communications Fellowship Grants
2020-01-13 12:30 ET
Cytokinetics Announces Vision 2025 and Outlines 2020 Corporate Milestones
2020-01-06 12:30 ET
Cytokinetics Announces Start of Redwood-HCM, a Phase 2 Clinical Trial of CK-3773274
2019-12-18 12:30 ET
Cytokinetics Granted Orphan Drug Designation for Reldesemtiv for the Treatment of Amyotrophic Lateral Sclerosis
2019-12-05 12:30 ET
Cytokinetics Announces New Results Presented at the International Symposium on ALS/MND
2019-11-27 21:00 ET
Cytokinetics to Participate in the Piper Jaffray Healthcare Conference
2019-11-26 21:00 ET
Cytokinetics Announces Five Presentations at the International Symposium on ALS/MND
2019-11-18 14:00 ET
New Results From COSMIC-HF Presented At AHA 2019 Show Treatment Of Heart Failure Patients With Omecamtiv Mecarbil Was Associated With Neutral Or Improved Measures Of Diastolic Function
2019-11-18 14:00 ET
New Results From COSMIC-HF Presented at AHA 2019 Show Treatment of Heart Failure Patients With Omecamtiv Mecarbil Was Associated With Neutral or Improved Measures of Diastolic Function
2019-11-11 14:00 ET
Cytokinetics Announces Additional Results From COSMIC-HF to be Presented at the American Heart Association Scientific Sessions 2019
2019-11-08 12:30 ET
Cytokinetics Announces Pricing of Public Offering of Convertible Senior Notes
2019-11-06 21:05 ET
Cytokinetics Announces Proposed Public Offering of Convertible Senior Notes
2019-11-05 12:30 ET
Cytokinetics to Participate in the Credit Suisse 28th Annual Healthcare Conference
2019-10-31 20:00 ET
Cytokinetics Reports Third Quarter 2019 Financial Results
2019-10-24 20:00 ET
Cytokinetics to Announce Third Quarter Results on October 31, 2019
2019-10-04 11:30 ET
Cytokinetics Announces Presentation of Additional Analyses From FORTITUDE-ALS at the 18th Annual NEALS Meeting
2019-09-26 20:00 ET
Cytokinetics to Present at the Cantor Fitzgerald Global Healthcare Conference
2019-09-26 20:00 ET
Cytokinetics Announces Additional Results From FORTITUDE-ALS to be Presented at the 18th Annual NEALS Meeting
2019-09-25 11:30 ET
Cytokinetics Announces Second Annual Communications Fellowship Program Call for Proposals
2019-09-16 11:30 ET
Cytokinetics Announces Data From Phase 1 Study of CK-3773274 at the HFSA 23ʳᵈ Annual Scientific Meeting
2019-09-06 20:00 ET
Cytokinetics Announces Presentations at the 23rd Annual HFSA Scientific Meeting
2019-03-20 12:30 ET
Amgen, Cytokinetics and Servier Announce Continuation of GALACTIC-HF Following Planned Interim Analysis
2019-03-11 16:04 ET
Cytokinetics Announces Additional Results From COSMIC-HF to be Presented at ACC.19
2019-03-07 21:10 ET
Cytokinetics Announces Presentation of Results From FORTITUDE-ALS at the American Academy of Neurology 71st Annual Meeting
2019-02-28 12:30 ET
Cytokinetics Joins Global Initiative To Recognize International Rare Disease Day
2019-02-21 13:30 ET
Amgen, Cytokinetics and Servier Announce Start of METEORIC-HF, the Second Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure

SEC forms

Show financial reports only

SEC form 8
2026-05-08 20:05 ET
Cytokinetics published news for 2026 q1
SEC form 8
2026-05-08 20:05 ET
Cytokinetics published news for 2026 q1
SEC form 8
2026-05-08 20:05 ET
Cytokinetics published news for 2026 q1
SEC form 8
2026-05-05 20:12 ET
Cytokinetics published news for 2026 q1
SEC form 8
2026-05-05 20:12 ET
Cytokinetics published news for 2026 q1
SEC form 10
2026-05-05 20:06 ET
Cytokinetics published news for 2026 q1
SEC form 8
2026-05-05 20:05 ET
Cytokinetics published news for 2026 q1
SEC form 8
2026-05-05 20:05 ET
Cytokinetics published news for 2026 q1
SEC form 10
2026-02-26 16:01 ET
Cytokinetics published news for 2025 q4
SEC form 8
2026-02-24 16:13 ET
Cytokinetics published news for 2025 q4
SEC form 8
2026-02-24 16:13 ET
Cytokinetics reported for 2025 q4
SEC form 10
2025-11-05 21:31 ET
Cytokinetics reported for 2025 q3
SEC form 8
2025-11-05 21:00 ET
Cytokinetics published news for 2025 q3
SEC form 8
2025-11-05 21:00 ET
Cytokinetics reported for 2025 q3
SEC form 8
2025-09-08 21:02 ET
Cytokinetics published news for 2025 q2
SEC form 8
2025-09-08 21:02 ET
Cytokinetics published news for 2025 q2
SEC form 8
2025-09-02 21:34 ET
Cytokinetics published news for 2025 q2
SEC form 8
2025-09-02 21:34 ET
Cytokinetics published news for 2025 q2
SEC form 8
2025-09-02 21:20 ET
Cytokinetics published news for 2025 q2
SEC form 8
2025-09-02 21:20 ET
Cytokinetics published news for 2025 q2
SEC form 10
2025-08-07 20:30 ET
Cytokinetics reported for 2025 q2
SEC form 8
2025-08-07 20:01 ET
Cytokinetics published news for 2025 q2
SEC form 8
2025-08-07 20:01 ET
Cytokinetics reported for 2025 q2
SEC form 10
2025-05-06 20:30 ET
Cytokinetics reported for 2025 q1
SEC form 8
2025-05-06 20:05 ET
Cytokinetics published news for 2025 q1
SEC form 8
2025-05-06 20:05 ET
Cytokinetics reported for 2025 q1
SEC form 10
2025-05-06 00:00 ET
Cytokinetics reported for 2025 q1
SEC form 10
2025-02-27 17:05 ET
Cytokinetics reported for 2024 q4
SEC form 8
2025-02-27 16:05 ET
Cytokinetics published news for 2024 q4
SEC form 8
2025-02-27 16:05 ET
Cytokinetics reported for 2024 q4
SEC form 10
2025-02-27 00:00 ET
Cytokinetics reported for 2024 q4
SEC form 10
2024-11-07 16:05 ET
Cytokinetics reported for 2024 q3
SEC form 10
2024-08-09 16:05 ET
Cytokinetics reported for 2024 q2
SEC form 10
2024-08-09 00:00 ET
Cytokinetics reported for 2024 q2
SEC form 8
2024-08-08 16:01 ET
Cytokinetics published news for 2024 q2
SEC form 8
2024-08-08 16:01 ET
Cytokinetics reported for 2024 q2
SEC form 10
2024-05-10 00:00 ET
Cytokinetics reported for 2024 q1
SEC form 8
2024-05-08 00:00 ET
Cytokinetics published news for 2024 q1
SEC form 8
2024-05-08 00:00 ET
Cytokinetics reported for 2024 q1
SEC form 10
2024-02-28 17:12 ET
Cytokinetics reported for 2023 q4
SEC form 10
2024-02-28 00:00 ET
Cytokinetics reported for 2023 q4
SEC form 8
2024-02-27 16:05 ET
Cytokinetics published news for 2023 q4
SEC form 8
2024-02-27 16:05 ET
Cytokinetics reported for 2023 q4
SEC form 10
2023-11-03 17:30 ET
Cytokinetics reported for 2023 q3
SEC form 10
2023-11-03 00:00 ET
Cytokinetics reported for 2023 q3
SEC form 8
2023-11-02 16:05 ET
Cytokinetics reported for 2023 q3
SEC form 10
2023-08-03 16:14 ET
Cytokinetics reported for 2023 q2
SEC form 6
2023-08-03 16:00 ET
Cytokinetics reported for 2023 q2
SEC form 10
2023-08-03 00:00 ET
Cytokinetics reported for 2023 q2
SEC form 8
2023-08-03 00:00 ET
Cytokinetics reported for 2023 q2
SEC form 10
2023-05-05 00:00 ET
Cytokinetics reported for 2023 q1
SEC form 8
2023-05-04 00:00 ET
Cytokinetics reported for 2023 q1
SEC form 6
2023-03-31 07:33 ET
Cytokinetics published news for 2022 q4
SEC form 6
2023-03-06 07:02 ET
Cytokinetics published news for 2022 q4
SEC form 10
2023-03-01 16:07 ET
Cytokinetics reported for 2022 q4
SEC form 6
2023-03-01 16:01 ET
Cytokinetics reported for 2022 q4
SEC form 10
2023-03-01 00:00 ET
Cytokinetics reported for 2022 q4
SEC form 8
2023-03-01 00:00 ET
Cytokinetics reported for 2022 q4
SEC form 6
2023-02-24 17:02 ET
Cytokinetics published news for 2022 q4
SEC form 6
2023-02-17 16:46 ET
Cytokinetics published news for 2022 q4
SEC form 6
2023-01-09 07:01 ET
Cytokinetics published news for 2022 q4
SEC form 6
2022-12-13 17:47 ET
Cytokinetics published news for 2022 q3
SEC form 6
2022-12-08 16:04 ET
Cytokinetics published news for 2022 q3
SEC form 6
2022-12-08 07:31 ET
Cytokinetics published news for 2022 q3
SEC form 6
2022-12-07 07:33 ET
Cytokinetics published news for 2022 q3
SEC form 6
2022-11-07 07:30 ET
Cytokinetics published news for 2022 q3
SEC form 10
2022-11-04 16:42 ET
Cytokinetics reported for 2022 q3
SEC form 10
2022-11-04 00:00 ET
Cytokinetics reported for 2022 q3
SEC form 6
2022-11-03 16:06 ET
Cytokinetics reported for 2022 q3
SEC form 8
2022-11-03 00:00 ET
Cytokinetics reported for 2022 q3
SEC form 6
2022-10-11 07:31 ET
Cytokinetics published news for 2022 q3
SEC form 6
2022-10-03 09:00 ET
Cytokinetics published news for 2022 q3
SEC form 6
2022-09-30 16:30 ET
Cytokinetics published news for 2022 q2
SEC form 10
2022-08-05 16:06 ET
Cytokinetics published news for 2022 q2
SEC form 10
2022-08-05 00:00 ET
Cytokinetics reported for 2022 q2
SEC form 6
2022-08-04 16:04 ET
Cytokinetics published news for 2022 q2
SEC form 6
2022-08-04 16:03 ET
Cytokinetics published news for 2022 q2
SEC form 8
2022-08-04 00:00 ET
Cytokinetics reported for 2022 q2
SEC form 6
2022-07-06 16:31 ET
Cytokinetics published news for 2022 q2
SEC form 6
2022-06-24 07:30 ET
Cytokinetics published news for 2022 q1
SEC form 6
2022-06-17 07:35 ET
Cytokinetics published news for 2022 q1
SEC form 6
2022-06-16 07:30 ET
Cytokinetics published news for 2022 q1
SEC form 6
2022-06-13 07:30 ET
Cytokinetics published news for 2022 q1
SEC form 6
2022-05-27 17:15 ET
Cytokinetics published news for 2022 q1
SEC form 6
2022-05-23 11:30 ET
Cytokinetics published news for 2022 q1
SEC form 6
2022-05-18 07:30 ET
Cytokinetics published news for 2022 q1
SEC form 6
2022-05-17 07:30 ET
Cytokinetics published news for 2022 q1
SEC form 6
2022-05-11 16:01 ET
Cytokinetics published news for 2022 q1
SEC form 10
2022-05-06 16:02 ET
Cytokinetics published news for 2022 q1
SEC form 10
2022-05-06 00:00 ET
Cytokinetics reported for 2022 q1
SEC form 6
2022-05-04 16:00 ET
Cytokinetics published news for 2022 q1
SEC form 8
2022-05-04 00:00 ET
Cytokinetics reported for 2022 q1
SEC form 6
2022-04-15 16:33 ET
Cytokinetics published news for 2022 q1
SEC form 6
2022-04-08 16:05 ET
Cytokinetics published news for 2022 q1
SEC form 6
2022-04-08 16:00 ET
Cytokinetics published news for 2022 q1
SEC form 6
2022-04-04 16:01 ET
Cytokinetics published news for 2022 q1
SEC form 6
2022-04-04 16:00 ET
Cytokinetics published news for 2022 q1
SEC form 6
2022-04-01 16:00 ET
Cytokinetics published news for 2022 q1
SEC form 6
2022-03-02 07:30 ET
Cytokinetics published news for 2021 q4
SEC form 6
2022-03-01 16:00 ET
Cytokinetics published news for 2021 q4
SEC form 6
2022-03-01 16:00 ET
Cytokinetics published news for 2021 q4
SEC form 6
2022-02-28 07:30 ET
Cytokinetics published news for 2021 q4
SEC form 10
2022-02-25 17:01 ET
Cytokinetics published news for 2021 q4
SEC form 10
2022-02-25 00:00 ET
Cytokinetics published news for 2021 q4
SEC form 6
2022-02-24 16:00 ET
Cytokinetics published news for 2021 q4
SEC form 8
2022-02-24 00:00 ET
Cytokinetics published news for 2021 q4
SEC form 6
2022-02-23 07:30 ET
Cytokinetics published news for 2021 q4
SEC form 6
2022-02-16 16:00 ET
Cytokinetics published news for 2021 q4
SEC form 6
2022-02-16 07:30 ET
Cytokinetics published news for 2021 q4
SEC form 6
2022-02-15 07:30 ET
Cytokinetics published news for 2021 q4
SEC form 6
2022-02-04 07:30 ET
Cytokinetics published news for 2021 q4
SEC form 6
2022-02-01 16:00 ET
Cytokinetics published news for 2021 q4
SEC form 6
2022-02-01 07:30 ET
Cytokinetics published news for 2021 q4
SEC form 6
2022-01-24 07:30 ET
Cytokinetics published news for 2021 q4
SEC form 6
2022-01-07 07:30 ET
Cytokinetics published news for 2021 q4
SEC form 6
2021-12-20 07:30 ET
Cytokinetics published news for 2021 q3
SEC form 6
2021-12-10 07:30 ET
Cytokinetics published news for 2021 q3
SEC form 6
2021-12-09 07:30 ET
Cytokinetics published news for 2021 q3
SEC form 6
2021-12-01 16:00 ET
Cytokinetics published news for 2021 q3
SEC form 6
2021-11-15 07:30 ET
Cytokinetics published news for 2021 q3
SEC form 10
2021-11-05 16:04 ET
Cytokinetics published news for 2021 q3
SEC form 10
2021-11-05 00:00 ET
Cytokinetics published news for 2021 q3
SEC form 6
2021-11-03 16:00 ET
Cytokinetics published news for 2021 q3
SEC form 8
2021-11-03 00:00 ET
Cytokinetics published news for 2021 q3
SEC form 6
2021-11-01 16:00 ET
Cytokinetics published news for 2021 q3
SEC form 6
2021-10-29 07:30 ET
Cytokinetics published news for 2021 q3
SEC form 6
2021-10-07 16:01 ET
Cytokinetics published news for 2021 q3
SEC form 6
2021-10-01 16:11 ET
Cytokinetics published news for 2021 q3
SEC form 6
2021-09-13 07:30 ET
Cytokinetics published news for 2021 q2
SEC form 6
2021-09-01 16:00 ET
Cytokinetics published news for 2021 q2
SEC form 6
2021-08-19 07:30 ET
Cytokinetics published news for 2021 q2
SEC form 6
2021-08-18 16:00 ET
Cytokinetics published news for 2021 q2
SEC form 10
2021-08-06 16:06 ET
Cytokinetics published news for 2021 q2
SEC form 10
2021-08-06 00:00 ET
Cytokinetics published news for 2021 q2
SEC form 6
2021-08-05 16:00 ET
Cytokinetics published news for 2021 q2
SEC form 8
2021-08-05 00:00 ET
Cytokinetics published news for 2021 q2
SEC form 6
2021-08-02 16:00 ET
Cytokinetics published news for 2021 q2
SEC form 6
2021-08-02 07:30 ET
Cytokinetics published news for 2021 q2
SEC form 6
2021-07-23 12:45 ET
Cytokinetics published news for 2021 q2
SEC form 6
2021-07-21 16:25 ET
Cytokinetics published news for 2021 q2
SEC form 8
2021-07-21 00:00 ET
Cytokinetics published news for 2021 q2
SEC form 6
2021-07-19 16:11 ET
Cytokinetics published news for 2021 q2
SEC form 6
2021-07-19 09:42 ET
Cytokinetics published news for 2021 q2
SEC form 6
2021-07-19 07:30 ET
Cytokinetics published news for 2021 q2
SEC form 6
2021-07-01 16:00 ET
Cytokinetics published news for 2021 q2
SEC form 6
2021-06-30 07:30 ET
Cytokinetics published news for 2021 q1
SEC form 6
2021-06-15 07:30 ET
Cytokinetics published news for 2021 q1
SEC form 6
2021-06-01 16:45 ET
Cytokinetics published news for 2021 q1
SEC form 6
2021-05-19 07:30 ET
Cytokinetics published news for 2021 q1
SEC form 6
2021-05-17 16:02 ET
Cytokinetics published news for 2021 q1
SEC form 6
2021-05-13 16:00 ET
Cytokinetics published news for 2021 q1
SEC form 10
2021-05-07 16:12 ET
Cytokinetics published news for 2021 q1
SEC form 10
2021-05-07 00:00 ET
Cytokinetics published news for 2021 q1
SEC form 6
2021-05-06 16:00 ET
Cytokinetics published news for 2021 q1
SEC form 6
2021-05-06 07:30 ET
Cytokinetics published news for 2021 q1
SEC form 8
2021-05-06 00:00 ET
Cytokinetics published news for 2021 q1
SEC form 6
2021-05-04 07:30 ET
Cytokinetics published news for 2021 q1
SEC form 6
2021-05-03 16:14 ET
Cytokinetics published news for 2021 q1
SEC form 6
2021-04-30 16:00 ET
Cytokinetics published news for 2021 q1
SEC form 6
2021-04-12 07:30 ET
Cytokinetics published news for 2021 q1
SEC form 6
2021-04-07 16:05 ET
Cytokinetics published news for 2021 q1
SEC form 6
2021-04-01 16:00 ET
Cytokinetics published news for 2021 q1
SEC form 6
2021-03-11 16:39 ET
Cytokinetics published news for 2020 q4
SEC form 6
2021-02-26 18:00 ET
Cytokinetics published news for 2020 q4
SEC form 10
2021-02-26 16:33 ET
Cytokinetics published news for 2020 q4
SEC form 6
2021-02-26 07:30 ET
Cytokinetics published news for 2020 q4
SEC form 6
2021-02-25 16:00 ET
Cytokinetics published news for 2020 q4
SEC form 6
2021-02-24 07:30 ET
Cytokinetics published news for 2020 q4
SEC form 6
2021-02-19 16:19 ET
Cytokinetics published news for 2020 q4
SEC form 6
2021-02-18 07:30 ET
Cytokinetics published news for 2020 q4
SEC form 6
2021-02-02 07:30 ET
Cytokinetics published news for 2020 q4
SEC form 6
2021-02-01 16:00 ET
Cytokinetics published news for 2020 q4
SEC form 6
2021-01-13 07:30 ET
Cytokinetics published news for 2020 q4
SEC form 6
2021-01-11 07:30 ET
Cytokinetics published news for 2020 q4
SEC form 6
2020-12-23 07:30 ET
Cytokinetics published news for 2020 q3
SEC form 6
2020-12-14 07:30 ET
Cytokinetics published news for 2020 q3
SEC form 6
2020-12-09 07:30 ET
Cytokinetics published news for 2020 q3
SEC form 6
2020-12-07 07:30 ET
Cytokinetics published news for 2020 q3
SEC form 6
2020-12-01 16:00 ET
Cytokinetics published news for 2020 q3
SEC form 6
2020-11-23 07:30 ET
Cytokinetics published news for 2020 q3
SEC form 6
2020-11-20 07:30 ET
Cytokinetics published news for 2020 q3
SEC form 6
2020-11-16 07:30 ET
Cytokinetics published news for 2020 q3
SEC form 6
2020-11-16 07:30 ET
Cytokinetics published news for 2020 q3
SEC form 6
2020-11-16 07:30 ET
Cytokinetics published news for 2020 q3
SEC form 6
2020-11-13 11:35 ET
Cytokinetics published news for 2020 q3
SEC form 6
2020-11-10 16:01 ET
Cytokinetics published news for 2020 q3
SEC form 10
2020-11-06 16:03 ET
Cytokinetics published news for 2020 q3
SEC form 6
2020-11-04 16:00 ET
Cytokinetics published news for 2020 q3
SEC form 6
2020-10-08 13:21 ET
Cytokinetics published news for 2020 q3
SEC form 6
2020-10-05 16:00 ET
Cytokinetics published news for 2020 q3
SEC form 6
2020-10-05 07:30 ET
Cytokinetics published news for 2020 q3
SEC form 6
2020-10-02 07:30 ET
Cytokinetics published news for 2020 q3